Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

被引:910
作者
Law, MR [1 ]
Wald, NJ [1 ]
Morris, JK [1 ]
Jordan, RE [1 ]
机构
[1] Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2003年 / 326卷 / 7404期
关键词
D O I
10.1136/bmj.326.7404.1427
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the average reduction in blood pressure, prevalence of adverse effects, and reduction in risk of stroke and ischaemic heart disease events produced by the five main categories of blood pressure lowering drugs according to dose, singly and in combination. Design Meta-analysis of 354 randomised double blind placebo controlled trials of thiazides, beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin 11 receptor antagonists, and calcium channel blockers in fixed dose. Subjects 40 000 treated patients and 16 000 patients given placebo. Main outcome measures Placebo adjusted reductions in systolic and diastolic blood pressure and prevalence of adverse effects, according to dose expressed as a multiple of the standard (recommended) doses of the drugs. Results All five categories of drug produced similar reductions in blood pressure. The average reduction was 9.1 turn Hg systolic and 5.5 mm Hg diastolic at standard dose and 7.1 turn Hg systolic and 4.4 mm Hg diastolic (20% lower) at half standard dose. The drugs reduced blood pressure from all pretreatment levels, more so from higher levels; for a 10 mm Hg higher blood pressure the reduction was 1.0 mm Hg systolic and 1.1 mm Hg diastolic greater. The blood pressure lowering effects of different categories of drugs were additive. Symptoms attributable to thiazides, P blockers, and calcium channel blockers were strongly dose related; symptoms caused by ACE inhibitors (mainly cough) were not dose related. Angiotensin 11 receptor antagonists caused no excess of symptoms. The prevalence of symptoms with two drugs in combination was less than additive. Adverse metabolic effects (such as changes in cholesterol or potassium) were negligible at half standard dose. Conclusions Combination low dose drug treatment increases efficacy and reduces adverse effects. From the average blood pressure in people who have strokes (150/90 turn Hg) three drugs at half standard dose are estimated to lower blood pressure by 20 turn Hg systolic and 11 mm Hg diastolic and thereby reduce the risk of stroke by 63% and ischaemic heart disease events by 46% at age 60-69.
引用
收藏
页码:1427 / 1431
页数:7
相关论文
共 33 条
  • [1] *ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
  • [2] [Anonymous], 1981, LANCET, V2, P539
  • [3] ADDITIVE EFFECTS OF COMBINED ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND ANGIOTENSIN-II ANTAGONISM ON BLOOD-PRESSURE AND RENIN RELEASE IN SODIUM-DEPLETED NORMOTENSIVES
    AZIZI, M
    CHATELLIER, G
    GUYENE, TT
    MURIETAGEOFFROY, D
    MENARD, J
    [J]. CIRCULATION, 1995, 92 (04) : 825 - 834
  • [4] *BRIT MED ASS, 2001, BRIT NAT FORM SEPT 2
  • [5] *BRIT MED ASS ROYA, 2001, BRIT NAT FORM SEPT 2
  • [6] The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
    Bucher, HC
    Guyatt, GH
    Griffith, LE
    Walter, SD
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (06) : 683 - 691
  • [7] Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4
  • [8] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
    COLLINS, R
    PETO, R
    MACMAHON, S
    HEBERT, P
    FIEBACH, NH
    EBERLEIN, KA
    GODWIN, J
    QIZILBASH, N
    TAYLOR, JO
    HENNEKENS, CH
    [J]. LANCET, 1990, 335 (8693) : 827 - 838
  • [9] COUGH ASSOCIATED WITH CAPTOPRIL AND ENALAPRIL
    COULTER, DM
    EDWARDS, IR
    [J]. BRITISH MEDICAL JOURNAL, 1987, 294 (6586) : 1521 - 1523
  • [10] Meta-analyses involving cross-over trials: methodological issues
    Elbourne, DR
    Altman, DG
    Higgins, JPT
    Curtin, F
    Worthington, HV
    Vail, A
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2002, 31 (01) : 140 - 149